logo
Sign in

EDITAS MEDICINE, INC.

CAMBRIDGE, MA · Founded 2013 · Biotech · Public

CRISPR/Cas9-based gene therapy using AAV vectors to target and cleave latent HSV-1 genomes in neuronal cells

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · editasmedicine.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2013
Latest Form D
$120M, Aug 2015
Total capital
$120M
Federal grants
$225K
1 award · 2015
Rank in peer group#254 of 392
Private capital raised
$120M
1 Form D · last Aug 2015
134 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
15
25 pending · first 2024
Rank in peer group#1 of 392

Capital timeline

2015FEDERAL ↑EQUITY ↓Cumulative $120M$225K1st Form D$120M
2015FEDERAL ↑EQUITY ↓Cumulative $120M$225K1st Form D$120M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$120M
  • Federal grantHealth and Human S · Phase I · Vector-delivered CRISPR/Cas as a cure for HSV-1-induced keratitis$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

2months

from EDITAS MEDICINE, INC.’s first federal award to its first private round.

First federal award · Jul 2015
Health and Human S · $225K
First Form D · Aug 2015
$120M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#1 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alexandra GlucksmannExecutive OfficerNamed in SEC Form D filings
  • Alexis BorisyDirectorNamed in SEC Form D filings
  • Andrew HackExecutive OfficerNamed in SEC Form D filings
  • Boris NikolicDirectorNamed in SEC Form D filings
  • Douglas ColeDirectorNamed in SEC Form D filings
  • Katrine BosleyExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
  • Kevin BittermanDirectorNamed in SEC Form D filings
  • Vic MyerExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 15 granted of 40
  • New patentCompositions And Methods For Treating CEP290 Associated DiseaseUSPTOUS 12,760,330
  • PendingCrispr-related Methods And Compositions Targeting PTPN2 ExpressionUSPTOApplication 19398688
  • PendingCrispr-related Methods And Compositions Targeting FL1-1 ExpressionUSPTOApplication 19398931
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .